Secondary Hyperparathyroidism Due to Renal Causes Clinical Trial
Official title:
Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Renal Transplantation.
To demonstrate the superiority of paricalcitol treatment at early renal post-transplantation (M6) in the control of iPTH (Intact parathyroid hormone) compared to the use of vitamin D nutritional supplements (calcifediol) in patients with renal transplantation.
The purpose of this study is to demonstrate the superiority of paricalcitol treatment at early renal post-transplantation (M6) in the control of iPTH (Intact parathyroid hormone) compared to the use of vitamin D nutritional supplements (calcifediol) in patients with renal transplantation. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03588884 -
Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency
|
Phase 4 | |
| Active, not recruiting |
NCT03602261 -
Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI
|
Phase 2 | |
| Recruiting |
NCT05549154 -
A Study on Prevention Strategies for CKD-SHPT and Related Complications Based on General Vitamin D Supplementation
|
N/A | |
| Completed |
NCT04267965 -
Pulmonary Function, Voice and Swallowing Symptoms After Parathyroidectomy
|